Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MET inhibitor
Pharma
AstraZeneca dual lung cancer wins softened by bispecific fail
The successes of Enhertu and Orpathys-Tagrisso in lung cancer niches were overshadowed by the phase 3 crash of volrustomig in first-line NSCLC.
Angus Liu
Aug 17, 2026 10:56am
BMS-Eisai, China price cuts, AZ-Hutchmed—Fierce Pharma Asia
Jun 25, 2021 10:50am
AZ, HutchMed get China nod for Orpathys for rare type of NSCLC
Jun 23, 2021 11:17am
Merck KGaA matches Novartis with FDA green light for Tepmetko
Feb 4, 2021 12:09pm
Next-gen kinase inhibitors amp up cancer attacks—and M&A, too
Sep 17, 2020 8:45am
Novartis beats out Merck KGaA with lung cancer drug Tabrecta
May 6, 2020 3:07pm
